Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease

被引:81
作者
Boll, MC
Sotelo, J
Otero, E
Alcaraz-Zubeldia, M
Rios, C [1 ]
机构
[1] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Dept Neurochem, Mexico City, DF, Mexico
[2] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Dept Neurol, Mexico City, DF, Mexico
[3] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Dept Neuroimmunol, Mexico City, DF, Mexico
关键词
ferroxidase activity; cerebrospinal fluid; ceruloplasmin; Parkinson's disease; iron; copper;
D O I
10.1016/S0304-3940(99)00221-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Recent evidence suggest the implication of transition metals leading to overproduction of free radicals as a possible causal factor in the death of nigral cells associated to Parkinson's disease (PD). Iron depots in the basal ganglia of PD patients have been described; in addition, contents of nigral copper have been found decreased,while its concentration in cerebrospinal fluid (CSF) is raised, particularly the free form of the metal. To search for a possible link between altered copper concentrations and PD, we advanced the hypothesis that ferroxidase activity of ceruloplasmin is decreased in the CSF of PD patients. We studied 35 untreated PD patients, 14 L-3,4-dihydroxyphenylalanine (L-DOPA)-treated PD patients and 26 controls. Both CSF ferroxidase activity and CSF copper content were measured and correlated with the clinical stage of the disease. We found that untreated PD patients had a significant reduction of 40% in CSF ferroxidase while CSF copper was slightly increased as compared with both the values in L-DOPA-treated PD patients and controls. We also found that the fraction of copper linked to ferroxidase in untreated PD is inversely related to the clinical stage of the disease. (C) 1999 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:155 / 158
页数:4
相关论文
共 20 条
[1]  
ARNAUD P, 1988, METHOD ENZYMOL, V163, P441
[2]   EFFECT OF CH3HGCL AND SEVERAL TRANSITION-METALS ON THE DOPAMINE NEURONAL CARRIER - PECULIAR BEHAVIOR OF ZN2+ [J].
BONNET, JJ ;
BENMANSOUR, S ;
AMEJDKICHAB, N ;
COSTENTIN, J .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 266 (01) :87-97
[3]   Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals [J].
Crowe, A ;
Morgan, EH .
JOURNAL OF NUTRITION, 1996, 126 (01) :183-194
[4]   ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE-METALS IN PARKINSONS-DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA [J].
DEXTER, DT ;
CARAYON, A ;
JAVOYAGID, F ;
AGID, Y ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
BRAIN, 1991, 114 :1953-1975
[5]  
Fahn S., 1987, RECENT DEV PARKINSON, P153
[6]   ALTERED BRAIN METABOLISM OF IRON AS A CAUSE OF NEURODEGENERATIVE DISEASES [J].
GERLACH, M ;
BENSHACHAR, D ;
RIEDERER, P ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1994, 63 (03) :793-807
[7]   ACERULOPLASMINEMIA - MOLECULAR CHARACTERIZATION OF THIS DISORDER OF IRON-METABOLISM [J].
HARRIS, ZL ;
TAKAHASHI, Y ;
MIYAJIMA, H ;
SERIZAWA, M ;
MACGILLIVRAY, RTA ;
GITLIN, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2539-2543
[8]   DEFICIENCY OF COPPER CAN CAUSE NEURONAL DEGENERATION [J].
HARTMANN, HA ;
EVENSON, MA .
MEDICAL HYPOTHESES, 1992, 38 (01) :75-85
[9]   PARKINSONISM - ONSET PROGRESSION AND MORTALITY [J].
HOEHN, MM ;
YAHR, MD .
NEUROLOGY, 1967, 17 (05) :427-&
[10]   NEW INSIGHTS INTO THE CAUSE OF PARKINSONS-DISEASE [J].
JENNER, P ;
SCHAPIRA, AHV ;
MARSDEN, CD .
NEUROLOGY, 1992, 42 (12) :2241-2250